Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Scandic Hotels Group AB (publ) on an offering of convertible bonds and an extension of the existing credit facilities
Mandate

Vinge has advised Scandic Hotels Group AB (publ) on an offering of convertible bonds and an extension of the existing credit facilities

April 26, 2021 Banking and Finance Capital Markets and Public M&A

Vinge has advised Scandic Hotels Group AB (publ) on an offering of convertible bonds raising approximately SEK 1,609 million in gross proceeds and an extension of the existing SEK 6,650m credit facilities.

Scandic is the largest hotel company in the Nordic countries with about 58,000 rooms at approximately 280 hotels in operation and under development. Scandic is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team primarily consisted of Jesper Schönbeck, Amanda Knutsson, William Kåge and Anders Sundin Lundberg (Capital markets), Louise Brorsson Salomon, Linn Adelwald, Ludvig Wettergren and Rebecka Målquist (Banking and Finance).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025